You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFleroxacin
Accession NumberDB04576
TypeSmall Molecule
GroupsApproved
DescriptionFleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase.
Structure
Thumb
Synonyms
Fleroxacin
Fleroxacine
Fleroxacino
Fleroxacinum
Fleroxicin
FLRX
Megalocin
Megalocin (TN)
Megalone
Megalone (TN)
Megalosin
Quinodis
External Identifiers
  • UNII-N804LDH51K
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIN804LDH51K
CAS number79660-72-3
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationFleroxacin is a broad-spectrum antimicrobial fluoroquinolone.
Structured Indications Not Available
PharmacodynamicsFleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase.
Mechanism of actionThe inhibition of DNA gyrase and DNA topoisomerase 2 leads ultimately to cell death as these enzymes are required for bacterial DNA replication, transcription, repair, strand supercoiling repair, and recombination.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA topoisomerase 2-alphaProteinyes
inhibitor
HumanP11388 details
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
Related Articles
AbsorptionRapidly and well absorbed from the gastrointestinal tract after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Fleroxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fleroxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Fleroxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Fleroxacin.Experimental, Illicit
AcarboseFleroxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Fleroxacin.Approved
AcenocoumarolFleroxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Fleroxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Fleroxacin.Approved
AlbiglutideFleroxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Fleroxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Fleroxacin.Experimental
AlogliptinFleroxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Fleroxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Fleroxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Fleroxacin.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Fleroxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Fleroxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Fleroxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Fleroxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Fleroxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Fleroxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fleroxacin.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Fleroxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Fleroxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Fleroxacin.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Fleroxacin.Approved
BromocriptineFleroxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Fleroxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Fleroxacin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fleroxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CanagliflozinFleroxacin may increase the hypoglycemic activities of Canagliflozin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the neuroexcitatory activities of Fleroxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
ChlorpropamideFleroxacin may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Fleroxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Fleroxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fleroxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Fleroxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Fleroxacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Fleroxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Fleroxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Fleroxacin.Approved, Investigational
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Fleroxacin.Investigational
DapagliflozinFleroxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Fleroxacin.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Fleroxacin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Fleroxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Fleroxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Fleroxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fleroxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Fleroxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
DicoumarolFleroxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Fleroxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Fleroxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Fleroxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Fleroxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Fleroxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Fleroxacin.Approved
DisopyramideFleroxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fleroxacin.Approved, Investigational
DroxicamDroxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
DulaglutideFleroxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Fleroxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Fleroxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Fleroxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Fleroxacin.Investigational
EmpagliflozinFleroxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Fleroxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Fleroxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Fleroxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Fleroxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Fleroxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
Ethyl biscoumacetateFleroxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Fleroxacin.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Fleroxacin.Approved
ExenatideFleroxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Fleroxacin.Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Fleroxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
Ferric CarboxymaltoseThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FloctafenineFloctafenine may increase the neuroexcitatory activities of Fleroxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Fleroxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fleroxacin.Approved
FluindioneFleroxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Fleroxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Fleroxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Fleroxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Fleroxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Fleroxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Fleroxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Fleroxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Fleroxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Fleroxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Fleroxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fleroxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fleroxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Fleroxacin.Approved, Investigational, Withdrawn
GliclazideFleroxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideFleroxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFleroxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideFleroxacin may increase the hypoglycemic activities of Glyburide.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Fleroxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Fleroxacin.Investigational
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Fleroxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Fleroxacin.Approved, Vet Approved
IbuprofenIbuprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Fleroxacin.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
Insulin AspartFleroxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirFleroxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFleroxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFleroxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFleroxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFleroxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Fleroxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Fleroxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Fleroxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Fleroxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Fleroxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Fleroxacin.Approved
LanreotideFleroxacin may increase the hypoglycemic activities of Lanreotide.Approved
Lanthanum carbonateThe serum concentration of Fleroxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
LiraglutideFleroxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Fleroxacin.Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Fleroxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Fleroxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Fleroxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Fleroxacin.Investigational
MecaserminFleroxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Fleroxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Fleroxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
MetforminFleroxacin may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fleroxacin.Approved, Vet Approved
MifepristoneFleroxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolFleroxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Fleroxacin.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Fleroxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Fleroxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Fleroxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Fleroxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Fleroxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
NateglinideFleroxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Fleroxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Fleroxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Fleroxacin.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Fleroxacin.Approved, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Fleroxacin.Investigational
OctreotideFleroxacin may increase the hypoglycemic activities of Octreotide.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Fleroxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Fleroxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Fleroxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Fleroxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Fleroxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fleroxacin.Approved, Vet Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Fleroxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
PasireotideFleroxacin may increase the hypoglycemic activities of Pasireotide.Approved
PentamidineFleroxacin may increase the hypoglycemic activities of Pentamidine.Approved
PhenindioneFleroxacin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonFleroxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
PioglitazoneFleroxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Fleroxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
PramlintideFleroxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Fleroxacin.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Fleroxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fleroxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Fleroxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Fleroxacin.Experimental
ProbenecidThe serum concentration of Fleroxacin can be increased when it is combined with Probenecid.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Fleroxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Fleroxacin.Investigational
QuinaprilThe serum concentration of Fleroxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinineFleroxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideFleroxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Fleroxacin.Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Fleroxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Fleroxacin.Investigational, Withdrawn
RosiglitazoneFleroxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalicylamideSalicylamide may increase the neuroexcitatory activities of Fleroxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Fleroxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Fleroxacin.Approved
SaxagliptinFleroxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
SevelamerSevelamer can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinFleroxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SRT501SRT501 may increase the neuroexcitatory activities of Fleroxacin.Investigational
Strontium ranelateThe serum concentration of Fleroxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Fleroxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineFleroxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleFleroxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
SulfisoxazoleFleroxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Fleroxacin.Approved
SunitinibFleroxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Fleroxacin.Approved, Withdrawn
TenoxicamTenoxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Fleroxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Fleroxacin.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fleroxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Fleroxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Fleroxacin.Approved
TolazamideFleroxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideFleroxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Fleroxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Fleroxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Fleroxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Fleroxacin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Fleroxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Fleroxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Fleroxacin.Approved, Investigational
WarfarinFleroxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Fleroxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Fleroxacin.Withdrawn
Food Interactions
  • Avoid excessive coffee or tea (caffeine)
  • Avoid milk, calcium containing dairy products, iron, magnesium, zinc, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take with a full glass of water
  • Take without regard to meals
References
Synthesis Reference

DrugSyn.org

US4398029
General ReferencesNot Available
External Links
ATC CodesJ01MA08
AHFS Codes
  • 52:04.04
  • 8:12.18
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 dec °CPhysProp
logP0.24ROSS,DL ET AL. (1992) (ION-CORRECT)
Caco2 permeability-4.81ADME Research, USCD
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N: Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother. 1992 Apr;36(4):751-6. [PubMed:1323952 ]
  3. Hussy P, Maass G, Tummler B, Grosse F, Schomburg U: Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29(6):1073-8. [PubMed:3015015 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Naber KG: Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9. [PubMed:8861529 ]
  2. Asahina Y, Iwase K, Iinuma F, Hosaka M, Ishizaki T: Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin. J Med Chem. 2005 May 5;48(9):3194-202. [PubMed:15857125 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [PubMed:9293187 ]
  2. Chaudhry U, Ray K, Bala M, Saluja D: Mutation patterns in gyrA and parC genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India. Sex Transm Infect. 2002 Dec;78(6):440-4. [PubMed:12473806 ]
  3. Lee JK, Lee YS, Park YK, Kim BS: Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol Immunol. 2005;49(7):647-53. [PubMed:16034208 ]
  4. Leavis HL, Willems RJ, Top J, Bonten MJ: High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium. J Clin Microbiol. 2006 Mar;44(3):1059-64. [PubMed:16517894 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 09:20 / Updated on August 17, 2016 12:24